CYTUVA

GIR - Eye Surface Research Group (OSG)

Download PDF

Contact Information

Margarita Calonge Cano
Paseo de Belén, 17
Valladolid, Valladolid (47011)
Send email
983423274
983423723
http://www.web.ioba.es/nuestra-actividad/investigacion/grupos-de-investigacion/superficie-ocular/

Basic Information

UniversityUniversidad de Valladolid
CenterInstitute of Applied Ophthalmobiology (IOBA)
DepartmentSurgery, Ophthalmology, Otorhinolaryngology and Physiotherapy
Investigation GroupOcular Surface Research Group (GSO)

Description

PURPOSE OF THE GROUP.

Increase the efficiency of the current systems used in the reconstruction of the ocular surface inflammation (allergy, dry eye and others), both with medical means (new drugs, nanotechnology) and surgical means (tissue engineering).

GENERAL OBJECTIVES

1. Increase the effectiveness of current ocular surface transplants that have to be performed to restore corneal blindness.

2. Search for an alternative source of stem cells from the ocular surface different from the natural one (limbus), which avoids having to intervene in the contralateral healthy eye or having to obtain material from a histocompatible relative or cadaver, both cases requiring sustained systemic immunosuppression.

3. Find new therapeutic alternatives for chronic and serious inflammatory diseases of the ocular surface, specifically Allergies and Dry Eye Syndromes.

4. Application of nanotechnology to the development of controlled drug release systems for the recovery of ocular surface function.

Research lines

Research line 1: Advanced therapies (stem cells, tissue bioengineering) for ocular surface reconstruction.
Research line 2: Nanotechnological drug delivery systems based on biomaterials.
Research line 3: Severe Ocular Allergy: In vitro models and search for new drugs.
Research line 4: Dry Eye Syndrome.

Other information

Number of researchers:

Technological Line(s):

- Health Sciences

Development status:

In research and development phase

Intellectual Property Rights:

Susceptible registro Propiedad Intelectual

Differentiation in the market:

Quality

Applicability of technology:

Yes

Companies and markets:

Biotechnological, biomedical and pharmaceutical sector companies in the ophthalmological field.

Advantages:

The main objectives pursued by the GSO are:

Investigation into pathogenic inflammatory mechanisms on the ocular surface, through preclinical and clinical studies.
Identification and validation of biomarkers (cellular and molecular ones) of inflammatory ocular surface activity with the aim of improving the access to new drugs.
Increase in the cell therapy effectiveness in the treatment of ocular surface failure due to limbic insufficiency that causes corneal blindness.
Application of nanotechnology to the development of controlled drug delivery systems for the functional recovery of the ocular surface.
Execution of clinical trials that investigate the biological and molecular bases of the ocular surface in order to improve the treatments available to patients.

Additional Information:

The GSO belongs to several regional, national and international orgnizations:

Recognized Research Group (GIR) of the University of Valladolid
Consolidated Research Units (UIC) of the Junta de Castilla y Léon.
Member of the Network Center for Regenerative Medicine and Cell Therapy of Castilla y León (Castilla y León Board, Carlos III Health Institute (ISCIII))
Belongs to the Thematic Network of Cooperative Health Research (RETICS), specifically to the Cell Therapy Network (TerCel Network) and the Eye Pathology Network (OftaRed), ISCIII.
Belongs to the Spanish Nanomedicine Platform (NanomedSpain)
Integral Group of the Biomedical Network Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)
Belongs to the Cluster of Ophthalmology and Vision Sciences (Cluster4eye).

The GSO participates in numerous national and international projects, among which include:

International Drug Discovery and Delivery Project NEtwork for ONcology and Eye Therapeutics (3DNEONET), H2020-MSCA-RISE-2016, Grant Agreement no. 734907. There are 18 partners in total, from the academic and business world (www.3dneonet.org)
International Project Integrated Training in Dry Eye Disease Drug Development (IT-DED3), H2020-MSCA-ITN-ETN-2017, Grant Agreement no. 765608. 7 partners and 10 associated academic and non-academic bodies participate (www.itded3.eu)

UNESCO Code:

2407 - Cell biology

Other members:

Jose María Herreras Cantalapiedra
María Jesús González García
See more

Roberto Reinoso Tapia
Yolanda Diebold Luque
Teresa Nieto Miguel
Laura García Posadas
Alberto López Miguel

Photos

Videos

Other resources

Información GSO
See / Download resource

Related projects

Valorization of residual biomass

VALORIZATION OF BIOMASS BIOFUELS DISCARDED FROM THE LIGNOCELLULOSIC WASTE BIOMASS PRE-TREATMENT TECHNOLOGIES, ENZYMATIC HYDROLYSIS AND BIOCONVERSION OF SUGARS INTO BIOFUELS. - Main researcher: Silvia Bolado Rodríguez - PhD students: Rodolfo Travai... Read more >

University Institute of Applied Ophthalmobiology (IOBA)

The University Institute of Applied Ophthalmobiology of the University of Valladolid (IOBA) is a pioneering center, which was born within the University of Valladolid 25 years ago, with a triple aspect:ClinicResearcherTrainerThe IOBA competes in qual... Read more >

Controlled Environment Laboratory (CEL)

In the IOBA’ controlled environment laboratory (CEL), research studies and/or clinical trials are carried out to evaluate the ocular response from the clinical and biochemical point of view to an ocular treatment or to the wearing of contact lenses... Read more >

Ocular Pathological Anatomy Laboratory (LPO)

The Ocular Pathological Anatomy Laboratory of Valladolid’s University Institute of Applied Ophthalmology (IOBA) is a laboratory specialized in the study and diagnosis of samples belonging to eyeballs, orbit and ocular appendages. Diagnostic servi... Read more >

Generating PDF document